[111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: A pilot study

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 513-516

  Kälkner, Karl Mikael ^a,b   Nilsson, Sten ^a   Westlin, Jan Erik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hormone refractory; Neuroendocrine; Octreotide; Prostatic adenocarcinoma; Scintigraphy; Treatment

Indexed keywords

ESTRAMUSTINE; GONADORELIN; OCTREOTIDE; PENTETREOTIDE IN 111; PROSTATE SPECIFIC ANTIGEN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HORMONE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; PENTETIC ACID; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; GAMMA SCINTIGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SCINTIGRAPHY; TREATMENT OUTCOME; ADENOCARCINOMA; BONE TUMOR; EVALUATION; METASTASIS; MIDDLE AGED; PILOT STUDY; PROSTATE TUMOR; SCINTISCANNING;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; EVALUATION STUDIES; HORMONES; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; PILOT PROJECTS; PROSTATIC NEOPLASMS; SOMATOSTATIN;

EID: 0031596764     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cancer Incidence in Sweden 1960-1992: The National Board of Health and Welfare: Stockholm, Sweden, 1995.
2. Eisenberg MA: Chemotherapy for prostatic carcinoma. NCI Monographs 7: 151-163, 1988.
3. Yagoda A, Petrylak D Cytotoxic chemotherapy for advanced hormone-resistante prostate cancer. Cancer 71: 1098-1109, 1993.
4. Schally AV, Redding TW: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 84: 7275-7279, 1987.
5. Murphy W, Lance VA, Moreau S, Coy DH: Inhibition of rat prostate tumor growth by an octapeptideanalog of somatostatin. Life Sciences 40: 2515-2522, 1987.
6. Meyers F, Soares S, deVere White R: A phase II study of somatostatin in metastatic carcinoma of the prostate (CAP). Proc Annu Meet Am Soc Clin Oncol 10: A566, 1991.
7. Parmar H, Charlton CDA, Phillips RH, et al: Therpeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer. Clin Exp Metastasis 10: 3-11, 1992.
8. 111In]-labeled DTPA-D-[Phel]-Octreotide scintigraphy. Cancer Research 55: 5805s-5810s, 1995.
9. Kälkner KM, Ginman C, Westlin J-E, Letocha H, Nilsson S: Somatostatin Receptor Scintigraphy in Metastatic Hormone-Refractory Prostatic Carcinoma. Antib Immunoconjug Radiopharm 8: 11-21, 1995.
10. 111In-DTPA-D-Phel]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabellingand in vitrovalidation. Life Sciences 49: 1583-1591, 1991.
11. Abrahamsson P-A: Neuroendocrine differentiation and hormonerefractory prostate cancer. Prostate suppl 6: 3-8, 1996.
12. di Sant'Agnesi PA, Cockett ATK: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 152: 1927-1931, 1994.
13. Abrahamsson P-A, Falkmer S, Fait K, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 185: 373-380, 1989.
14. Kadmon D, Thompson T, Lynch G, Scardino P: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146: 358-361, 1991.
15. Tarle M, Rado's N: Investigation on.serum neurone-specific enolase in prostate cancer diagnosis and monitoring: Comparative study of a multiple tumor marker assay. Prostate 19: 23-33, 1991.
16. Aprikian AG, Cordon-Cardo C, Fair WR, et al: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 151: 914-919, 1994.
17. Reubi JC, Hacki WH, Lamberts SWJ: Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65: 1127-1134, 1987.
18. Reubi JC, Maurer R, von Werder K, Torhorts J, Klijn JGM, Lamberts SWJ: Somatostatin receptors in human endocrine tumors. Cancer Res 47: 551-558, 1987.
19. Westlin J-E, Tiensuu Janson E, Ahlstrom H, Nilsson S, Orhvall U, Oberg K: Scintigraphy using 111-Indium labelled somatostatin analouge for localization of neuroendocrine tumours. AntibImmunoconjug Radiopharm 5: 367-384, 1992.
20. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ: Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 20: 283-292,1993.
21. 1]-Octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 131: 577-578, 1994.
22. Verhelst J, de Longueville M, Ongena P, Denis L, Mahler C: Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 62: 82-88,1994.
23. Logothetis CJ, Hossan EA, Smith TL: SMS 201-995 in the treatment of refractory prostaticcarcinoma. Anticancer Res 14: 2731-2734, 1994.